Skip to content

Efficacy of Auricular Holographic Gua Sha Combined with Tangluoning Acupoint Application for Diabetic Peripheral Neuropathy (Qi-Deficiency and Blood-Stasis Pattern): A Randomized Controlled Trial

Efficacy of Auricular Holographic Gua Sha Combined with Tangluoning Acupoint Application for Diabetic Peripheral Neuropathy (Qi-Deficiency and Blood-Stasis Pattern): A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000393
Enrollment
Unknown
Registered
2026-02-13
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Peripheral Neuropathy

Interventions

Group A:Conventional treatment: patients will receive conventional treatment, including oral hypoglycemic agents or subcutaneous insulin injections for glycemic control
mecobalamin, B-complex vitamins, and other agents for nerve repair
Chinese herbal medicines to tonify Qi, promote blood circulation, resolve blood stasis, and unblock the collaterals to improve microcirculation
antidepressants and anticonvulsants to relieve neuropathic pain
and health education regarding diabetic complications. No TCM appropriate-technology interventions will be administered during the intervention period.
Group B:Conventional treatment plus auricular acupoint holographic Gua Sha
Group C:Conventional treatment plus Tangluoning acupoint application
Group D:Conventional treatment plus auricular acupoint holographic Gua Sha plus Tangluoning acupoint application

Sponsors

Longhua Hospital Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meet the Western medicine diagnostic criteria for diabetes mellitus (DM) and diabetic peripheral neuropathy (DPN);Diagnostic criteria were based on the Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2024 Edition) issued by the Chinese Diabetes Society (CDS).Diagnostic Criteria for Diabetes Mellitus (DM): Patients must present with typical symptoms of diabetes (polydipsia, polyuria, polyphagia, and unexplained weight loss) and meet any one of the following criteria:1)Random plasma glucose = 11.1 mmol/L;2)Fasting plasma glucose (FPG) = 7.0 mmol/L;3)2-hour plasma glucose = 11.1 mmol/L during an Oral Glucose Tolerance Test (OGTT);4)Glycated hemoglobin (HbA1c) = 6.5%. Diagnostic Criteria for Diabetic Peripheral Neuropathy (DPN):The diagnosis of DPN is established if at least 2 out of the following 5 criteria are met:1)A definite history of diabetes mellitus.2)The presence of neuropathy (predominantly peripheral) diagnosed at the time of or after the diagnosis of diabetes.3)The presence of clinical symptoms (numbness, pain, paresthesia) and signs (diminished or absent tendon reflexes; decreased or absent vibration sense; and varying degrees of impairment in tactile, temperature, pinprick, and pressure sensation).4)Exclusion of neuropathies caused by other etiologies.5)Electromyography (EMG) may be performed to confirm the diagnosis if the above examinations are inconclusive. (2) Meet the Traditional Chinese Medicine (TCM) pattern-differentiation criteria for the Qi-deficiency and blood-stasis pattern; (3) Aged 18–80 years (inclusive), either sex; receiving regular diabetes treatment with relatively stable glycemic control (fasting plasma glucose between 4.4 and 10.0 mmol/L within the past 3 months, and HbA1c < 8.5%); (4) Voluntarily agree to participate in the study and sign written informed consent; (5) Have good adherence and are able to cooperate with treatment (able to complete the 4-week treatment as specified in the study protocol).

Exclusion criteria

Exclusion criteria: (1) Neuropathy caused by other etiologies; (2) Contraindications to Gua Sha, or severe lower-extremity ulceration or gangrene; (3) Unable to cooperate with treatment, or with psychiatric disorders; (4) Serious diabetes-related complications, such as diabetic ketoacidosis, hyperosmolar hyperglycemic coma, or severe infection; (5) Severe diseases of major organ systems (e.g., cardiovascular, cerebrovascular, pulmonary, hepatic, splenic, or renal), or organic pathology such as malignancy; (6) Allergy to Tangluoning used in this study, or skin intolerance; (7) Any other condition for which the investigator deems the participant unsuitable for this study.

Design outcomes

Primary

MeasureTime frame
TCM symptom score;Toronto Clinical Scoring System;

Secondary

MeasureTime frame
Electromyography ;

Countries

China

Contacts

Public ContactYan Bai

Longhua Hospital Shanghai University of Traditional Chinese Medicine

by18435226348@163.com18435226348

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Mar 14, 2026